• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes.

作者信息

Bouchi Ryotaro, Kondo Tatsuya, Ohta Yasuharu, Goto Atsushi, Tanaka Daisuke, Satoh Hiroaki, Yabe Daisuke, Nishimura Rimei, Harada Norio, Kamiya Hideki, Suzuki Ryo, Yamauchi Toshimasa

机构信息

Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, Japan.

Department of Diabetes, Metabolism and Endocrinology, Kumamoto University Hospital, Kumamoto, Japan.

出版信息

J Diabetes Investig. 2023 Jan;14(1):151-164. doi: 10.1111/jdi.13960. Epub 2022 Dec 23.

DOI:10.1111/jdi.13960
PMID:36562245
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9807160/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/904b/9807160/1d95ffdb8815/JDI-14-151-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/904b/9807160/c704e98a13d9/JDI-14-151-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/904b/9807160/1d95ffdb8815/JDI-14-151-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/904b/9807160/c704e98a13d9/JDI-14-151-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/904b/9807160/1d95ffdb8815/JDI-14-151-g002.jpg

相似文献

1
A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes.日本糖尿病学会的共识声明：2型糖尿病患者药物治疗的建议算法。
J Diabetes Investig. 2023 Jan;14(1):151-164. doi: 10.1111/jdi.13960. Epub 2022 Dec 23.
2
A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes - 2nd edition (English version).日本糖尿病学会共识声明：2 型糖尿病药物治疗建议算法-第 2 版（英文版）。
J Diabetes Investig. 2024 Sep;15(9):1326-1342. doi: 10.1111/jdi.14202. Epub 2024 Jul 11.
3
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.2型糖尿病高血糖管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明
Diabetes Care. 2007 Jan;30(1):193-4. doi: 10.2337/dc06-2060.
4
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.2型糖尿病高血糖管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明
Diabetes Care. 2007 Jan;30(1):193; author reply 194-6. doi: 10.2337/dc06-1828.
5
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et al.2型糖尿病高血糖的医学管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明：对纳坦等人的回应
Diabetes Care. 2009 Mar;32(3):e35-6; author reply e37-8. doi: 10.2337/dc08-2275.
6
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.2型糖尿病高血糖管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明
Diabetes Care. 2007 Jan;30(1):190-2; author reply 194-6. doi: 10.2337/dc-06-1670.
7
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.2型糖尿病高血糖管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明
Diabetes Care. 2007 Jan;30(1):192-3; author reply 194-6. doi: 10.2337/dc06-1858.
8
Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.2型糖尿病高血糖管理：治疗起始与调整的共识算法。美国糖尿病协会和欧洲糖尿病研究协会的共识声明。
Diabetologia. 2006 Aug;49(8):1711-21. doi: 10.1007/s00125-006-0316-2.
9
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et al.2型糖尿病高血糖的医学管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明：对纳坦等人的回应
Diabetes Care. 2009 Mar;32(3):e34; author reply e37-8. doi: 10.2337/dc08-2093.
10
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et al.2型糖尿病高血糖管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明：对纳坦等人的回应
Diabetes Care. 2007 Apr;30(4):e16-7; author reply e18-20, e21-2. doi: 10.2337/dc06-2373.

引用本文的文献

1
Hypoglycemia-Related Hospitalization in Adults with Type 2 Diabetes Receiving Insulin in Japan: Real-World Analysis Using the Medical Data Vision Database.日本接受胰岛素治疗的2型糖尿病成人患者低血糖相关住院情况：使用医学数据视觉数据库的真实世界分析
Diabetes Ther. 2025 Aug 28. doi: 10.1007/s13300-025-01776-x.
2
Simultaneous Evaluation of Shear Wave Elastography and C-Peptide Index for Predicting Need of Insulin Therapy in Type 2 Diabetes: A Pilot Study.剪切波弹性成像与C肽指数同步评估预测2型糖尿病胰岛素治疗需求的初步研究
J Pers Med. 2025 Jul 1;15(7):277. doi: 10.3390/jpm15070277.
3
Myricetin Amplifies Glucose-Stimulated Insulin Secretion via the cAMP-PKA-Epac-2 Signaling Cascade.

本文引用的文献

1
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.9. 血糖治疗的药物学方法：《2022 年糖尿病医学诊疗标准》。
Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143. doi: 10.2337/dc22-S009.
2
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.钠-葡萄糖协同转运蛋白 2 抑制剂达格列净治疗射血分数保留的心力衰竭：一项多中心随机试验。
Nat Med. 2021 Nov;27(11):1954-1960. doi: 10.1038/s41591-021-01536-x. Epub 2021 Oct 28.
3
Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
杨梅素通过cAMP-PKA-Epac-2信号级联放大葡萄糖刺激的胰岛素分泌。
Biomedicines. 2025 Jun 12;13(6):1447. doi: 10.3390/biomedicines13061447.
4
Clinical use and monitoring of adverse effects of sodium-glucose cotransporter-2 inhibitors in persons with type 1 diabetes mellitus.1型糖尿病患者中钠-葡萄糖协同转运蛋白2抑制剂的临床应用及不良反应监测
J Diabetes Investig. 2025 Aug;16(8):1420-1429. doi: 10.1111/jdi.70085. Epub 2025 May 26.
5
Cost-Effectiveness Analysis of SGLT2 Inhibitors for Cardio-Renal-Metabolic Disease Based on Data from Japanese Studies.基于日本研究数据的SGLT2抑制剂治疗心肾代谢疾病的成本效益分析。
Adv Ther. 2025 Jun;42(6):2888-2905. doi: 10.1007/s12325-025-03157-z. Epub 2025 Apr 29.
6
Transitional changes in medication-initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes-A hospital-based cohort study in Japan.慢性肾脏病和2型糖尿病患者用药起始人群特征的过渡性变化——日本一项基于医院的队列研究
Diabetes Obes Metab. 2025 Jul;27(7):3714-3724. doi: 10.1111/dom.16394. Epub 2025 Apr 21.
7
Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study.启动胰高血糖素样肽-1受体激动剂治疗的2型糖尿病合并慢性肾脏病患者的临床特征及治疗模式：一项多国队列研究
Diabetes Ther. 2025 May;16(5):931-954. doi: 10.1007/s13300-025-01717-8. Epub 2025 Mar 19.
8
Burden of Current Insulin Therapy and Expectations for Future Insulin Therapy: Results from INBEING, a Web-Based Survey in Japan.当前胰岛素治疗的负担及对未来胰岛素治疗的期望：来自日本一项基于网络的INBEING调查的结果
Diabetes Ther. 2024 Dec;15(12):2537-2555. doi: 10.1007/s13300-024-01664-w. Epub 2024 Nov 1.
9
Role of Triglyceride-Glucose Index in Type 2 Diabetes Mellitus and Its Complications.甘油三酯-葡萄糖指数在2型糖尿病及其并发症中的作用
Diabetes Metab Syndr Obes. 2024 Sep 4;17:3325-3333. doi: 10.2147/DMSO.S478287. eCollection 2024.
10
Sulfonylurea prescription patterns in elderly patients with type 2 diabetes mellitus: A comprehensive analysis of real-world data from pharmacies in Japan.磺酰脲类药物在老年 2 型糖尿病患者中的处方模式：来自日本药店真实世界数据的综合分析。
J Diabetes Investig. 2024 Nov;15(11):1604-1613. doi: 10.1111/jdi.14302. Epub 2024 Sep 3.
18 项心血管结局试验中血糖控制的改善和主要心血管事件的减少：更新的荟萃回归分析。
Cardiovasc Diabetol. 2021 Oct 18;20(1):210. doi: 10.1186/s12933-021-01401-8.
4
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
5
Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan.回顾性全国研究：日本 2 型糖尿病患者一线抗糖尿病药物的趋势。
J Diabetes Investig. 2022 Feb;13(2):280-291. doi: 10.1111/jdi.13636. Epub 2021 Aug 17.
6
Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018.美国成年人糖尿病治疗和控制的趋势，1999-2018 年。
N Engl J Med. 2021 Jun 10;384(23):2219-2228. doi: 10.1056/NEJMsa2032271.
7
Comparison of the contributions of impaired beta cell function and insulin resistance to the development of type 2 diabetes in a Japanese community: the Hisayama Study.在一个日本社区中，比较β细胞功能障碍和胰岛素抵抗对 2 型糖尿病发展的贡献：Hisayama 研究。
Diabetologia. 2021 Aug;64(8):1775-1784. doi: 10.1007/s00125-021-05459-7. Epub 2021 Apr 28.
8
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有糖尿病的慢性肾脏病患者的主要不良肾脏和心血管事件的影响：来自 DAPA-CKD 试验的预先指定分析。
Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7.
9
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
10
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.钠-葡萄糖协同转运蛋白 2 抑制剂在射血分数降低的心力衰竭患者中的应用：EMPEROR-Reduced 和 DAPA-HF 试验的荟萃分析。
Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.